Open AccessRelationship of cytokine level dynamics with longterm results of early rheumatoid arthritis therapy
Author(s) -
V. Rybakova,
А. С. Авдеева,
Д. А. Дибров,
Е. Л. Насонов
Publication year - 2022
Publication title -
naučno-praktičeskaâ revmatologiâ
Language(s) - English
Resource type - Journals
eISSN - 1995-4492
pISSN - 1995-4484
DOI - 10.47360/1995-4484-2022-72-79
Subject(s) - medicine , rheumatoid arthritis , proinflammatory cytokine , cytokine , disease , multiplex , immunology , gastroenterology , antibody , rheumatoid factor , inflammation , bioinformatics , biology
The aim of the work – to research the relationship between the dynamics of cytokine levels in the early period (the first 12 and 24 weeks) of pharmacotherapy for rheumatoid arthritis (RA) and long-term outcomes in patients with the disease. Material and methods. The analysis included 93 patients with early RA. The majority of patients were women (n=77), middle-aged (58 [49; 66] years), with an early stage of the disease (the duration of the disease is 7 [4–11.5] months), seropositive according to IgM rheumatoid factor and cyclic citrullinated peptide antibodies, who had high (59.7%) or moderate (38.8%) disease activity.The concentration of 27 cytokines in the blood serum was determined with the help of multiplex xMAP technology on the Bio-Plex array system analyzer (BIORAD, USA). Repeated clinical examination of patients was carried out after 6 years. Results . Patients who achieved remission/low disease activity SDAI after 6 years had a lower level of IL-6 (7.7 [7.4; 23.3]), IL-9 (13.5 [9.1; 18.9]) 12 weeks after the start of therapy; lower IL-9 level (12.6 [6.8; 16.2]) 24 weeks after the start of the treatment, compared with the group of patients with moderate and high inflammatory activity (23.5 [12.4; 69.5], 17.8 [15; 29] and 18.5 [14.2; 22.8] respectively). Findings. The assessment of the level of proinflammatory cytokines (IL-6, IL-17), immunoregulatory cytokine IL-9 allows to evaluate the activity of the disease more fully and identify a group of patients, who needs the therapy intensification.